Table 2. Statin Prescription Outcomes of the Integrating Pharmacogenetics in Clinical Care Study.
| Outcome | Participants, No. (%) | |
|---|---|---|
| Genotyping results known at baseline (n = 193) | Genotyping results known at 12 mo (n = 215) | |
| Statin offered by physician | 65 (33.7) | 69 (32.1) |
| Statin declineda | 42 (64.6) | 50 (72.5) |
| Statin prescribeda | 26 (40.0) | 24 (34.8) |
| Statin adherenceb | 9 (45.0) | 9 (45.0) |
| Statin discontinued | 3 (11.5) | 4 (16.7) |
| ACC-AHA concordance at 12 moc | 12 (6.2) | 14 (6.5) |
| CPIC concordance at 12 mod | 193 (100.0) | 215 (100.0) |
Abbreviations: ACC-AHA, American College of Cardiology–American Heart Association; CPIC, Clinical Pharmacogenetics Implementation Consortium.
a
Percentages may sum to more than 100% because a patient could both initially decline statin therapy and then be prescribed statin therapy later during the observation period.
b
Denotes the number of participants with proportion of days covered by medication possession greater than or equal to 80% from statin initiation through the end of study enrollment; calculable denominators for each group are 20 participants.
c
P < .001, corresponding to 1-sided noninferiority test assuming margin of 15% favoring control.
d
P > .99, corresponding to 2-sided test for superiority.